🔎 Trials Near Me

Utama › Leukemia Mieloid Akut › Minnesota

Kajian klinikal Leukemia Mieloid Akut di Minnesota

27 kajian untuk Leukemia Mieloid Akut sedang mencari peserta di lokasi di Minnesota.

Bandar di Minnesota

Teks kajian rasmi (Bahasa Inggeris)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Riverwood Healthcare Center, Aitkin
  • Mayo Clinic Health System in Albert Lea, Albert Lea
  • Essentia Health - Baxter Clinic, Baxter
  • dan 48 lagi
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • Mercy Hospital, Coon Rapids
  • Essentia Health - Deer River Clinic, Deer River
  • Essentia Health Cancer Center, Duluth
  • dan 8 lagi
Mengambil pesertaFasa 2
Umur 18 hingga 59 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT05554393

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Mercy Hospital, Coon Rapids
  • Essentia Health - Deer River Clinic, Deer River
  • Essentia Health Cancer Center, Duluth
  • dan 8 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05564390

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

  • University of Minnesota/Masonic Cancer Center, Minneapolis
Mengambil pesertaFasa 1
Sehingga umur 21 · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07012044

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • Mercy Hospital, Coon Rapids
  • Essentia Health - Deer River Clinic, Deer River
  • Essentia Health Cancer Center, Duluth
  • dan 8 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  • Mercy Hospital, Coon Rapids
  • Essentia Health - Deer River Clinic, Deer River
  • Essentia Health Cancer Center, Duluth
  • dan 8 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • Mercy Hospital, Coon Rapids
  • Essentia Health - Deer River Clinic, Deer River
  • Essentia Health Cancer Center, Duluth
  • dan 9 lagi
Mengambil pesertaFasa 2
Umur 18 hingga 59 · Semua jantina · Dikemas kini 22 Sep 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
  • University of Minnesota/Masonic Cancer Center, Minneapolis
  • Mayo Clinic in Rochester, Rochester
Mengambil pesertaFasa 3
6 Months – 21 Years · Semua jantina · Dikemas kini 17 Sep 2026 · NCT04293562

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

  • Mayo Clinic, Rochester
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT04588922

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  • US-Rochester MN-MAYOMN, Rochester
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT06652438

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
  • University of Minnesota/Masonic Cancer Center, Minneapolis
  • Mayo Clinic in Rochester, Rochester
Mengambil pesertaFasa 1/2
Sehingga umur 22 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  • Masonic Cancer Center, Minneapolis
Mengambil pesertaFasa 3
29 Days – 21 Years · Semua jantina · Dikemas kini 24 Ogo 2026 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • University of Minnesota, Minneapolis
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT07007312

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

  • Masonic Cancer Center, Minneapolis
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Jul 2026 · NCT07008638

HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

  • Masonic Cancer Center, Minneapolis
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Jul 2026 · NCT06594445

Allo HSCT Using RIC and PTCy for Hematological Diseases

  • Masonic Cancer Center at University of Minnesota, Minneapolis
Mengambil pesertaFasa 2
Sehingga umur 75 · Semua jantina · Dikemas kini 6 Jul 2026 · NCT05805605

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

  • Masonic Cancer Center at University of Minnesota, Minneapolis
Mengambil pesertaFasa 2
Sehingga umur 60 · Semua jantina · Dikemas kini 25 Jun 2026 · NCT03314974

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

  • Mark Juckett, MD, Minneapolis
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Mei 2026 · NCT07591649

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

  • Masonic Cancer Center at University of Minnesota, Minneapolis
Mengambil pesertaFasa 2
Umur 2 hingga 75 · Semua jantina · Dikemas kini 16 Apr 2026 · NCT07493538

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

  • Mayo Clinic Comprehensive Cancer Center, Rochester
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Apr 2026 · NCT05732103

Backtracking Leukemia-Typical Somatic Mutations in Cord Blood

  • University of Minnesota/Masonic Cancer Center, Minneapolis
Mengambil pesertaKajian pemerhatian
Sehingga umur 25 · Semua jantina · Dikemas kini 8 Apr 2026 · NCT05014165

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

  • University of Minnesota Masonic Cancer Center, Minneapolis
Mengambil pesertaFasa 2
Sehingga umur 60 · Semua jantina · Dikemas kini 6 Apr 2026 · NCT05735717

Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy

  • Mayo Clinic in Rochester, Rochester
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Apr 2026 · NCT06279572

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • University of Minnesota, Minneapolis
  • Mayo Clinic - Rochester, Rochester
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Mac 2026 · NCT05735184

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

  • Mayo Clinic, Rochester
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Feb 2026 · NCT06950034

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

  • Mayo Clinic, Rochester
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 18 hingga 120 · Semua jantina · Dikemas kini 25 Jul 2025 · NCT05237258

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.